Skip to content
DataLookout
Menu

NCT07944885

First-in-human Study of SAR448632 in Healthy Adult Participants

StatusNot Yet Recruiting
PhasePhase 1
SponsorSanofi
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Number of participants with assessment of Adverse Events (AEs) / Treatment-Emergent Adverse Events (TEAEs), including Injection Site Reactions (ISRs)
Timeframe: Baseline to day 113
Number of participants with potentially clinically significant abnormalities in clinical laboratory evaluation; Vital signs; 12-lead Electrocardiogram.
Timeframe: Baseline to day 113

Secondary (5)

Maximum observed plasma concentration (Cmax )
Time to reach maximum observed plasma concentration (tmax )
Area under the plasma concentration-time curve (AUC)
Area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUC last ).
Incidence of participants with presence of Anti-Drug Antibody (ADA) against SAR448632.

Arms and interventions

SAR448632Experimental

Participants will receive a single dose of SAR448632 by SC injection or infusion on Day 1 only.

PlaceboPlacebo comparator

The placebo administration will match the dosing planned for SAR448632

Drugs: Placebo, SAR448632